Evaluation and management of insomnia in women with breast cancer.

Abstract:

PURPOSE:Insomnia is a common issue among patients with breast cancer with a potentially devastating impact on quality of life. It can be caused or exacerbated by multiple disease and treatment-related factors. Despite the prevalence and impact of insomnia, it is rarely addressed systematically in the oncology clinic. We conducted a comprehensive review of insomnia to guide clinical care of patient's with breast cancer and insomnia. METHODS:This manuscript reviews the prevalence, etiology, emerging science and both non-pharmacologic and pharmacologic options for treatment of insomnia among patients with breast cancer. RESULTS:Multiple factors contribute to insomnia among patients with breast cancer including endocrine therapy and hotflashes, pain and discomfort from local therapy, and fear of recurrence. If we do identify insomnia, there are treatment options and strategies available to help patients. In particular, there is now a considerable body of evidence supporting the use of psychosocial interventions and behavioral treatments, such as cognitive behavioral therapy for insomnia (CBT-I), yoga, and mind-body programs. It is also important for oncology providers to be educated regarding available pharmacologic therapies and emerging data for cannabis-based therapy. CONCLUSION:This manuscript provides an up-to-date and comprehensive review of the prevalence, etiology, and treatment approaches available for insomnia for clinicians treating patients with breast cancer. We also address strategies and goals for cancer care delivery and future research.

authors

Kwak A,Jacobs J,Haggett D,Jimenez R,Peppercorn J

doi

10.1007/s10549-020-05635-0

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

269-277

issue

2

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-020-05635-0

journal_volume

181

pub_type

杂志文章,评审
  • Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.

    abstract:PURPOSE:Body composition parameters including low muscle mass, muscle attenuation (which reflects muscle quality) and adipose tissue measurements have emerged as prognostic factors in cancer patients. However, knowledge regarding the possibility of excessive muscle loss during specific systemic therapies is unknown. We...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4574-0

    authors: Rier HN,Jager A,Sleijfer S,van Rosmalen J,Kock MCJM,Levin MD

    更新日期:2018-02-01 00:00:00

  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).

    abstract:PURPOSE:To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ ("older"). METHODS:Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-017-4353-y

    authors: Bluethmann SM,Alfano CM,Clapp JD,Luta G,Small BJ,Hurria A,Cohen HJ,Sugarman S,B Muss H,Isaacs C,Mandelblatt JS

    更新日期:2017-10-01 00:00:00

  • Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population.

    abstract::Genome-Wide Association Studies have identified several loci associated with breast cancer (BC) in populations of different ethnic origins. One of the strongest associations was found in the FGFR2 gene, and MAP3K1 has been proposed as a low-penetrance BC risk factor. In this study, we evaluated the associations among ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2359-z

    authors: Jara L,Gonzalez-Hormazabal P,Cerceño K,Di Capua GA,Reyes JM,Blanco R,Bravo T,Peralta O,Gomez F,Waugh E,Margarit S,Ibañez G,Romero C,Pakomio J,Roizen G

    更新日期:2013-01-01 00:00:00

  • Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.

    abstract:PURPOSE:Although tamoxifen remains the frontline treatment for ERα-positive breast cancers, resistance to this drug limits its clinical efficacy. Most tamoxifen-resistant patients retain ERα expression which may support growth and progression of breast cancers. Therefore, we investigated epigenetic regulation of ERα th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05517-0

    authors: Kim SS,Lee MH,Lee MO

    更新日期:2020-02-01 00:00:00

  • Polyamines metabolism and breast cancer: state of the art and perspectives.

    abstract::Breast cancer (BC) is a common disease that generally occurs in women over the age of 50, and the risk is especially high for women over 60 years of age. One of the major BC therapeutic problems is that tumors initially responsive to chemotherapeutic approaches can progress to more aggressive forms poorly responsive t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-014-3156-7

    authors: Cervelli M,Pietropaoli S,Signore F,Amendola R,Mariottini P

    更新日期:2014-11-01 00:00:00

  • A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

    abstract:PURPOSE:Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. R...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-020-05626-1

    authors: Watanabe J,Saito M,Horimoto Y,Nakamoto S

    更新日期:2020-05-01 00:00:00

  • Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.

    abstract:PURPOSE:Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4579-8

    authors: Brouckaert O,Van Asten K,Laenen A,Soubry A,Smeets A,Nevelstreen I,Vergote I,Wildiers H,Paridaens R,Van Limbergen E,Weltens C,Moerman P,Floris G,Neven P,Multidisciplinary breast centre Leuven.

    更新日期:2018-02-01 00:00:00

  • LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.

    abstract::Lysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. We analyzed the prognostic impact of LOXL2 for breast cancer patients and investigated the role of LOXL2 in breast cancer cell lines. Immunohistochemical study of LOXL2 expression was done in samples from 309 patients. Surviv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2662-3

    authors: Ahn SG,Dong SM,Oshima A,Kim WH,Lee HM,Lee SA,Kwon SH,Lee JH,Lee JM,Jeong J,Lee HD,Green JE

    更新日期:2013-08-01 00:00:00

  • PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.

    abstract::It has recently been proposed that a three-gene model (SCMGENE) that measures ESR1, ERBB2, and AURKA identifies the major breast cancer intrinsic subtypes and provides robust discrimination for clinical use in a manner very similar to a 50-gene subtype predictor (PAM50). However, the clinical relevance of both predict...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2143-0

    authors: Prat A,Parker JS,Fan C,Perou CM

    更新日期:2012-08-01 00:00:00

  • Older women's experience with breast cancer treatment decisions.

    abstract::The purpose of this study was to better understand older women's experience with breast cancer treatment decisions. We conducted a longitudinal study of non-demented, English-speaking women ≥ 65 years recruited from three Boston-based breast imaging centers. We interviewed women at the time of breast biopsy (before th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2921-y

    authors: Schonberg MA,Birdwell RL,Bychkovsky BL,Hintz L,Fein-Zachary V,Wertheimer MD,Silliman RA

    更新日期:2014-05-01 00:00:00

  • Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.

    abstract:PURPOSE:The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). However, the studies in the overview were to a large content performed before mode...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4007-5

    authors: Nordenskjöld A,Fohlin H,Fornander T,Löfdahl B,Skoog L,Stål O

    更新日期:2016-11-01 00:00:00

  • MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.

    abstract::NF-E2-related factor 2 (Nrf2) is an important transcription factor involved in antioxidant response. Nrf2 binds antioxidant response elements (ARE) within promoters of genes encoding detoxification enzymes (e.g., NAD (P) H-quinone oxidoreductase 1 (NQO1)) leading to their transcriptional activation. Nrf2 function is r...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1604-1

    authors: Yang M,Yao Y,Eades G,Zhang Y,Zhou Q

    更新日期:2011-10-01 00:00:00

  • Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

    abstract::The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2- and 9-months assessments. A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1084-8

    authors: Svensson H,Einbeigi Z,Johansson H,Hatschek T,Brandberg Y

    更新日期:2010-10-01 00:00:00

  • The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin.

    abstract::A detailed analysis of the immune system response has been performed during the development and progression of dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. For this aim, a number of immune parameters (thymocyte and splenocyte proliferative response to T-dependent mitogens, antibody production, lymphocy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665692

    authors: Gallo F,Morale MC,Sambataro D,Farinella Z,Scapagnini U,Marchetti B

    更新日期:1993-09-01 00:00:00

  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract::Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005951125574

    authors: Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期:1998-03-01 00:00:00

  • Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.

    abstract::Anthracyclines are among the most powerful antineoplastic drugs available for breast cancer treatment. Although HER2 amplification has been postulated to predict anthracycline benefit, numerous reports have demonstrated that HER2/TOP2A co-amplification is the clinically useful predictive marker of response to anthracy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2791-8

    authors: García-Caballero T,Prieto O,Vázquez-Boquete A,Gude F,Viaño P,Otero M,Curiel T,Fernández-Rodríguez B,Parrado C,Fraga M,Antúnez JR

    更新日期:2014-01-01 00:00:00

  • Diagnostic work-up of contralateral breast cancers has not improved over calendar period.

    abstract::Women who have been treated for breast cancer are typically followed up with regular mammography and palpation, with the aim of detecting recurrences and contralateral breast cancer (CBC). This study aims to investigate if the diagnostic work-up of breast cancer patients has improved over the last 25 years and resulte...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0748-8

    authors: Sandberg ME,Hartman M,Edgren G,Eloranta S,Ploner A,Hall P,Czene K

    更新日期:2010-08-01 00:00:00

  • Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

    abstract::Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0329-x

    authors: Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

    更新日期:2010-01-01 00:00:00

  • Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.

    abstract::Our aim was to develop an accurate diagnostic system using gene expression analysis by means of DNA microarray for prognosis of node-negative and estrogen receptor (ER)-positive breast cancer patients in order to identify a subset of patients who can be safely spared adjuvant chemotherapy. A diagnostic system comprisi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1145-z

    authors: Naoi Y,Kishi K,Tanei T,Tsunashima R,Tominaga N,Baba Y,Kim SJ,Taguchi T,Tamaki Y,Noguchi S

    更新日期:2011-08-01 00:00:00

  • The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.

    abstract::The basal-like or basal phenotype (BP) class of breast cancers have recently attracted attention as a poor prognostic form of breast cancer. However, BP appears to encompass biologically and clinically heterogeneous tumours, resulting in a lack of consensus definition of BP. We analysed 48,000 gene transcripts in 132 ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0450-x

    authors: Zhang H,Rakha EA,Ball GR,Spiteri I,Aleskandarany M,Paish EC,Powe DG,Macmillan RD,Caldas C,Ellis IO,Green AR

    更新日期:2010-05-01 00:00:00

  • Structural and functional studies of insulin receptors in human breast cancer.

    abstract::We characterized the structure and the function of insulin receptors isolated from 10 human breast cancer specimens. We observed that the insulin receptor content, as determined by a specific radioimmunoassay, was four fold increased in human breast cancer tissue when compared to normal breast tissues. In both cancer ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00662403

    authors: Frittitta L,Vigneri R,Papa V,Goldfine ID,Grasso G,Trischitta V

    更新日期:1993-01-01 00:00:00

  • Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

    abstract:PURPOSE:Tobacco smoking is a risk factor in several cancers, yet its roles as a putative etiologic exposure or poor prognostic factor in breast cancer are less clear. Altered DNA methylation contributes to breast cancer development and may provide a mechanistic link between smoking and gene expression changes leading t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4178-8

    authors: Conway K,Edmiston SN,Parrish E,Bryant C,Tse CK,Swift-Scanlan T,McCullough LE,Kuan PF

    更新日期:2017-06-01 00:00:00

  • Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.

    abstract:PURPOSE:Dysregulation of HER2 signaling pathway in breast cancer is well documented. Our bioinformatics analysis predicted hsa-miR-512-3p (miR-512-3p) as a bona fide regulator of HER2 as well as HER3, PIK3R2, and AKT1 genes. Then, we intended to examine the effect of miR-512-3p on the predicted target genes that are in...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05937-3

    authors: Mohamadzade Z,Mahjoubi F,Soltani BM

    更新日期:2021-01-01 00:00:00

  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.

    abstract:PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06012-7

    authors: Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

    更新日期:2020-11-18 00:00:00

  • Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.

    abstract:PURPOSE:Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4037-z

    authors: Janssen N,Fortis SP,Speigl L,Haritos C,Sotiriadou NN,Sofopoulos M,Arnogiannaki N,Stavropoulos-Giokas C,Dinou A,Perez S,Pawelec G,Baxevanis CN,Shipp C

    更新日期:2017-01-01 00:00:00

  • Triple negative breast cancer: unmet medical needs.

    abstract::Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2 (HER2) overexpression. It shows substantial overlap with basal-...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-1293-1

    authors: Pal SK,Childs BH,Pegram M

    更新日期:2011-02-01 00:00:00

  • Methylthioadenosine phosphorylase in human breast cancer.

    abstract::Methylthioadenosine (MTA) phosphorylase activity was measured in 47 biopsies from primary breast cancers (n = 34) and metastatic tumors (n = 13). Most specimens were also evaluated by DNA flow cytometry and determination of estrogen and progesterone receptor contents. Median MTA phosphorylase activity was 317 pmol/mg ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806694

    authors: Smaaland R,Schanche JS,Kvinnsland S,Høstmark J,Ueland PM

    更新日期:1987-01-01 00:00:00

  • What is the future of magnetic nanoparticles in the axillary management of breast cancer?

    abstract::Magnetic nanoparticles (MNPs) possess unique properties, which make them highly attractive for medical applications. The use of MNPs in surgery has mainly been focused on their role in the identification of metastatic lymph node involvement. There have been developments within this field, including ongoing and newly c...

    journal_title:Breast cancer research and treatment

    pub_type: 社论

    doi:10.1007/s10549-013-2801-x

    authors: Ahmed M,Douek M

    更新日期:2014-01-01 00:00:00

  • G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.

    abstract::Analysis of germline p53 mutations in breast cancer reveals that the Li-Fraumeni and Li-Fraumeni-like syndromes are mostly related to the loss of initiation codon 133 of regulatory TP53 isoforms (Delta133p53). In eight codons of exons 5-8 (including 133), mutations are frequent in Li-Fraumeni-related, but scarce in sp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9514-y

    authors: Kouidou S,Malousi A,Kyventidis A,Fragou A,Maglaveras N

    更新日期:2007-12-01 00:00:00

  • Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer.

    abstract::Fresh organically grown pomegranates (Punica granatum L.) of the Wonderful cultivar were processed into three components: fermented juice, aqueous pericarp extract and cold-pressed or supercritical CO2-extracted seed oil. Exposure to additional solvents yielded polyphenol-rich fractions ('polyphenols') from each of th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014405730585

    authors: Kim ND,Mehta R,Yu W,Neeman I,Livney T,Amichay A,Poirier D,Nicholls P,Kirby A,Jiang W,Mansel R,Ramachandran C,Rabi T,Kaplan B,Lansky E

    更新日期:2002-02-01 00:00:00